Related Experiment Videos
DNA content as a prognostic factor in endometrial carcinoma
R Newbury1, C Schuerch, N Goodspeed
1Department of Laboratory Medicine, Geisinger Medical Center, Danville, Pennsylvania.
Obstetrics and Gynecology
|August 1, 1990
Summary
Aneuploidy in endometrial cancer, detected by DNA analysis, strongly predicts disease-related death, especially in high-grade or papillary serous types. This DNA content may guide adjuvant therapy decisions for specific patient subgroups.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- Endometrial carcinoma is a common gynecologic malignancy.
- Accurate prognostic markers are crucial for treatment stratification.
- DNA content analysis offers potential insights into tumor behavior.
Purpose of the Study:
- To investigate the prognostic value of DNA content analysis in endometrial carcinoma.
- To correlate DNA ploidy status with clinicopathologic features and patient outcomes.
- To identify potential applications of DNA analysis in treatment selection.
Main Methods:
- Flow cytometry was used to analyze DNA content in cell nuclei from 233 archival endometrial carcinoma paraffin blocks.
- Median follow-up was 8.7 years.
- Correlation of DNA index and cell cycle phases with histologic type, grade, invasion depth, stage, and patient survival was performed.
Main Results:
- Aneuploidy was found in 18% of tumors and associated with adverse histologic type, high grade, and deep myometrial invasion.
- Aneuploidy was absent in low-grade carcinomas.
- A DNA index > 1.5 was a strong predictor of death from disease, independent of stage or grade in adenocarcinomas and papillary serous carcinomas.
- S phase or G2+M phase percentages did not predict outcome in diploid tumors.
Conclusions:
- DNA content analysis, particularly aneuploidy and a DNA index > 1.5, serves as a significant prognostic marker in endometrial carcinoma.
- DNA analysis may aid in selecting patients with low-stage, high-grade, or papillary serous endometrial cancers for adjuvant therapy.
- Further application of DNA content analysis could refine risk stratification and personalize treatment strategies.